Shire delivers record annual results in 2015

Shire has announced its financial results for 2015, during which it delivered a record annual revenue total of $6.42 billion (4.49 billion pounds).

This represents a year-on-year increase of seven percent, while its non-GAAP diluted earnings per share increase by ten percent to $11.68. The company expressed satisfaction with what was described as a transformative year for Shire.

During the last 12 months, sales of key products such as Vyvanse, Cinryze, Firazyr, Lialda/Mezavent and Natpara all grew, while it was able to significantly progress its pipeline, with 14 programmes either in phase III testing or deemed phase III-ready.

Meanwhile, it was able to grow its business with the acquisitions of NPS and Dyax, which will be followed soon by the planned merger with Baxalta.

The firm expects to generate double-digit topline growth and a seven to ten percent increase in non-GAAP diluted earnings per share in 2016.

Dr Flemming Ornskov, chief executive officer of Shire, said: "With the acquisition of Dyax and the planned combination with Baxalta, we are positioned for global leadership in rare diseases."